Johnson & Johnson announced an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ in patients with relapsed or refractory multiple myeloma showed that patients treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy as well as BCMA and anti-Fc receptor-like protein 5 bispecific antibodies, after TALVEY™ treatment.
